Our patented Sound Bites platform offers a convenient, unbiased way for oncologists to stay up-to-date.

Critical, on-demand information right at your fingertips when and where it is most convenient for you. Subscribe to receive 60 – 90 second video clips from thought leaders via text message.

Credible oncology updates at your fingertips.

Free. No ads. No bias.

Browse Clinical Trial Updates

All
Breast Cancer
Conference Updates
GI Cancers
GU Cancers
GYN Oncology
Hematologic Malignancies
Lung Cancer
Skin Cancer
Dr. Laura van ‘t Veer discusses baseline ctDNA as a predictive marker in neoadjuvant breast cancer (Video 1/3)

Dr. Laura van ‘t Veer discusses baseline ctDNA as a predictive marker in neoadjuvant breast cancer (Video 1/3)

ctDNA Baseline

Laura van 't Veer, PhD
Breast Cancer
Dr. Arnab Basu reviews ctDNA risk status as a predictor of recurrence in bladder cancer (Video 2/3)

Dr. Arnab Basu reviews ctDNA risk status as a predictor of recurrence in bladder cancer (Video 2/3)

ctDNA Risk Stratification

Arnab Basu, MD
GU Cancers
Dr. Arnab Basu discusses ctDNA as a predictive marker in bladder cancer (Video 1/3)

Dr. Arnab Basu discusses ctDNA as a predictive marker in bladder cancer (Video 1/3)

ctDNA Predictive

Arnab Basu, MD
GU Cancers
Dr. Manali Kamdar describes best practices and impact of timing for CAR-T utilization in patients with LBCL (Video 3/3)

Dr. Manali Kamdar describes best practices and impact of timing for CAR-T utilization in patients with LBCL (Video 3/3)

Best practices

Manali Kamdar, MD
Hematologic Malignancies
Dr. Edgardo Santos describes the management of patients receiving SQ amivantamab-based regimens (Video 3/3)

Dr. Edgardo Santos describes the management of patients receiving SQ amivantamab-based regimens (Video 3/3)

Ami Pt Mgmt

Edgardo Santos, MD
Lung Cancer
Dr. Amer Zeidan describes the patient management with luspatercept including RS negative and EPO <200 (Video 3/3)

Dr. Amer Zeidan describes the patient management with luspatercept including RS negative and EPO <200 (Video 3/3)

COMMANDS Outcomes

Amer Zeidan, MD
Hematologic Malignancies

Why subscribe?

  • Get one-minute, non-promotional, educational videos from distinguished thought leaders
  • Tailored to topics you select
    • Breast Cancer
    • Lung Cancer
    • Gastrointestinal Cancers
    • Genitourinary Cancers
    • Gynecologic Cancers
    • Hemotologic Malignancies
    • Conference updates and more
  • No spam. No ads. No apps to download.
  • Always free and you can opt-out anytime if you feel this isn’t for you.

Fill out the form above to subscribe!

Our patented Sound Bites platform offers a convenient, unbiased way for oncologists to stay up-to-date.

Critical, on-demand information right at your fingertips when and where it is most convenient for you. Subscribe to receive 60 – 90 second video clips from thought leaders via text message.

Intended for USA healthcare providers only.

If your institution is not listed, please input the Institution / Company name in the field below.

By clicking Subscribe, I agree that I have read and understand IDEOlogy Health’s Privacy Policy and Terms and Conditions and further agree to receive information from IDEOlogy Health and its companies

ideology-health
Privacy Policy
Terms of Service
Inc. 5000

IDEOlogy Health Ranks No. 772 on the 2025 Inc. 5000 Fastest-Growing Private Companies in America

© 2025 IDEOlogy Health. All product names, logos, brands, trademarks and registered trademarks are property of their respective owners and their use(s) do not necessarily imply endorsement.